Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H1 2016

Description:

The report ‘Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H1 2016’, provides in depth analysis on Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted pipeline therapeutics.

The report provides comprehensive information on the Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2)
- The report reviews Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies
to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) Overview
Therapeutics Development

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Stage of Development

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Therapy Area

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Indication

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Products Glance

Late Stage Products
Early Stage Products

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Companies

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Companies Involved in Therapeutics Development

Amgen Inc.
Ascendis Pharma A/S
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drug Profiles

DE-117 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

ONO-8055 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

SAR-366234 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Small Molecule to Antagonize EP2 Receptor for Alzheimer's Disease - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

TG-4155 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

treprostinil - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Dormant Projects
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Discontinued Products
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Featured News & Press Releases

Apr 28, 2015: Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil
Jan 14, 2015: Ascendis Pharma Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil

Appendix

Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation

Contact Us
Disclaimer
List of Tables

Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Amgen Inc., H1 2016
Pipeline by Ascendis Pharma A/S, H1 2016
Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Pipeline by Sanofi, H1 2016
Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016

List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3766755/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address</td>
<td><a href="http://www.researchandmarkets.com/reports/3766755/">http://www.researchandmarkets.com/reports/3766755/</a></td>
</tr>
<tr>
<td>Office Code</td>
<td>SCD21WXR</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Site License</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World